Literature DB >> 11087738

A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Sträussler-Scheinker disease A117V.

F Tagliavini1, P M Lievens, C Tranchant, J M Warter, M Mohr, G Giaccone, F Perini, G Rossi, M Salmona, P Piccardo, B Ghetti, R C Beavis, O Bugiani, B Frangione, F Prelli.   

Abstract

Gerstmann-Sträussler-Scheinker disease (GSS) is a cerebral amyloidosis associated with mutations in the prion protein (PrP) gene (PRNP). The aim of this study was to characterize amyloid peptides purified from brain tissue of a patient with the A117V mutation who was Met/Val heterozygous at codon 129, Val(129) being in coupling phase with mutant Val117. The major peptide extracted from amyloid fibrils was a approximately 7-kDa PrP fragment. Sequence analysis and mass spectrometry showed that this fragment had ragged N and C termini, starting mainly at Gly88 and Gly90 and ending with Arg148, Glu152, or Asn153. Only Val was present at positions 117 and 129, indicating that the amyloid protein originated from mutant PrP molecules. In addition to the approximately 7-kDa peptides, the amyloid fraction contained N- and C-terminal PrP fragments corresponding to residues 23-41, 191-205, and 217-228. Fibrillogenesis in vitro with synthetic peptides corresponding to PrP fragments extracted from brain tissue showed that peptide PrP-(85-148) readily assembled into amyloid fibrils. Peptide PrP-(191-205) also formed fibrillary structures although with different morphology, whereas peptides PrP-(23-41) and PrP-(217-228) did not. These findings suggest that the processing of mutant PrP isoforms associated with Gerstmann-Sträussler-Scheinker disease may occur extracellularly. It is conceivable that full-length PrP and/or large PrP peptides are deposited in the extracellular compartment, partially degraded by proteases and further digested by tissue endopeptidases, originating a approximately 7-kDa protease-resistant core that is similar in patients with different mutations. Furthermore, the present data suggest that C-terminal fragments of PrP may participate in amyloid formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087738     DOI: 10.1074/jbc.M007062200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Nucleation-dependent conformational conversion of the Y145Stop variant of human prion protein: structural clues for prion propagation.

Authors:  Bishwajit Kundu; Nilesh R Maiti; Eric M Jones; Krystyna A Surewicz; David L Vanik; Witold K Surewicz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

2.  Molecular conformation and dynamics of the Y145Stop variant of human prion protein in amyloid fibrils.

Authors:  Jonathan J Helmus; Krystyna Surewicz; Philippe S Nadaud; Witold K Surewicz; Christopher P Jaroniec
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-24       Impact factor: 11.205

3.  Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype.

Authors:  Suman Jayadev; David Nochlin; Parvoneh Poorkaj; Ellen J Steinbart; James A Mastrianni; Thomas J Montine; Bernardino Ghetti; Gerard D Schellenberg; Thomas D Bird; James B Leverenz
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

4.  A novel PRNP-P105S mutation associated with atypical prion disease and a rare PrPSc conformation.

Authors:  E Tunnell; R Wollman; S Mallik; C J Cortes; S J Dearmond; J A Mastrianni
Journal:  Neurology       Date:  2008-10-28       Impact factor: 9.910

5.  In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression.

Authors:  Joëlle Chabry; Christiane Ratsimanohatra; Isabelle Sponne; Pierre-Paul Elena; Jean-Pierre Vincent; Thierry Pillot
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

6.  Live cell fluorescence resonance energy transfer predicts an altered molecular association of heterologous PrPSc with PrPC.

Authors:  Suparna Mallik; Wenbin Yang; Eric M Norstrom; James A Mastrianni
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

7.  Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3.

Authors:  Mar Pérez; Ana I Rojo; Francisco Wandosell; Javier Díaz-Nido; Jesús Avila
Journal:  Biochem J       Date:  2003-05-15       Impact factor: 3.857

8.  Similar biochemical signatures and prion protein genotypes in atypical scrapie and Nor98 cases, France and Norway.

Authors:  Jean-Noël Arsac; Olivier Andreoletti; Jean-Marc Bilheude; Caroline Lacroux; Sylvie L Benestad; Thierry Baron
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

9.  Immunopurification of pathological prion protein aggregates.

Authors:  Emiliano Biasini; Laura Tapella; Susanna Mantovani; Matteo Stravalaci; Marco Gobbi; David A Harris; Roberto Chiesa
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

10.  Transmissibility of atypical scrapie in ovine transgenic mice: major effects of host prion protein expression and donor prion genotype.

Authors:  Jean-Noël Arsac; Dominique Bétemps; Eric Morignat; Cécile Féraudet; Anna Bencsik; Denise Aubert; Jacques Grassi; Thierry Baron
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.